This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Concordia Healthcare Corp.
Drug Names(s): Tranylcypromine sulfate
Description: Parnate is a non-hydrazine monoamine oxidase inhibitor with a rapid onset ofactivity. Parnate targets both Monoamine oxidase-A and monoamine oxidase-B. Studies indicate that it takes 30 days to reverse its binding, which makes it irreversible for all practical purposes. It increases the concentration of epinephrine, norepinephrine and serotonin in storagesites throughout the nervous system and, in theory, this increased concentration of monoaminesin the brain stem is the basis for its antidepressant activity.
GlaxoSmithKline and Covis
In December 2011, Covis Pharma Sarl announced an agreement with GlaxoSmithKline to acquire full commercial rights for Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate), and Zantac Injection (ranitidine hydrochloride) in the United States and Puerto Rico. GlaxoSmithKline will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed. GSK will manufacture and supply Fortaz Injection, Zinacef Injection, Parnate, and Zantac Injection to Covis. Lanoxin Tablets and Injection, Fortaz Frozen, Zinacef Frozen and Zantac Injection Premixed will continue to be manufactured and supplied by current third-party suppliers.
Covis and Concordia
In March 2015, Concordia Healthcare announced it has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Pink Sheet Par’s Generic Parnate Is On Par, FDA Says
Pink Sheet Nova
Pink Sheet SmithKline Beecham Paxil
Additional information available to subscribers only: